Predictive Oncology Files 8-K
Ticker: AGPU · Form: 8-K · Filed: Oct 8, 2025 · CIK: 1446159
Sentiment: neutral
Topics: 8-K, disclosure, financials
Related Tickers: PRED
TL;DR
PRED filed an 8-K on Oct 8th covering events from Oct 7th - check for updates.
AI Summary
Predictive Oncology Inc. filed an 8-K on October 8, 2025, reporting on events that occurred on October 7, 2025. The filing indicates a Regulation FD Disclosure and Other Events, along with Financial Statements and Exhibits. The company, formerly known as Skyline Medical Inc., is based in Pittsburgh, PA.
Why It Matters
This 8-K filing provides updates on significant company events and financial information, which are crucial for investors to assess the company's current status and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting on events and financial statements, not indicating any immediate significant risks.
Key Players & Entities
- Predictive Oncology Inc. (company) — Registrant
- October 7, 2025 (date) — Earliest event reported
- October 8, 2025 (date) — Date of report
- Skyline Medical Inc. (company) — Former company name
- Pittsburgh, PA (location) — Company business address
FAQ
What specific events are disclosed under Regulation FD Disclosure and Other Events?
The filing indicates these categories but does not detail the specific events within this excerpt.
When was Predictive Oncology Inc. formerly known as Skyline Medical Inc.?
The filing states the name change from Skyline Medical Inc. occurred in 20130807.
What is the primary business of Predictive Oncology Inc. according to its SIC code?
The company's SIC code is 3842, which corresponds to Orthopedic, Prosthetic & Surgical Appliances & Supplies.
Where is Predictive Oncology Inc. headquartered?
The company's business address is listed as 91 43RD STREET, SUITE 110, PITTSBURGH, PA 15201.
What is the filing date and the earliest event date reported in this 8-K?
The filing date is October 8, 2025, and the earliest event reported is October 7, 2025.
Filing Stats: 557 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2025-10-08 12:05:20
Key Financial Figures
- $0.01 — ange on which registered Common stock, $0.01 par value POAI Nasdaq Capital Market
Filing Documents
- f8k_100825.htm (8-K) — 16KB
- exh_991.htm (EX-99.1) — 11KB
- 0001171843-25-006348.txt ( ) — 225KB
- gnw-20250101.xsd (EX-101.SCH) — 3KB
- gnw-20250101_def.xml (EX-101.DEF) — 25KB
- gnw-20250101_lab.xml (EX-101.LAB) — 35KB
- gnw-20250101_pre.xml (EX-101.PRE) — 24KB
- f8k_100825_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On October 8, 2025, Predictive Oncology Inc. issued a press release announcing the closing of two private placements on October 7, 2025 and its adoption of a digital asset treasury strategy. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the " Exchange Act "), as amended, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Other Events
Item 8.01. Other Events. The information set forth in the press release referred to in Item 7.01 above, other than the fifth and sixth paragraphs thereof, is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description of Exhibit 99.1 Press Release, dated October 8, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Predictive Oncology Inc. Date: October 8, 2025 By: /s/ Josh Blacher Josh Blacher Interim Chief Financial Officer